Pearl S. Huang

Pearl Huang is a distinguished leader in the pharmaceutical and biotechnology sectors, currently serving as CEO and President of Dunad Therapeutics since May 2022, and as a Non-Executive Director at both BB Biotech and Waters Corporation. Previously, Pearl held the position of CEO at Cygnal Therapeutics and contributed significantly at Roche as SVP, heading a multi-national drug discovery organization. Pearl has an entrepreneurial background as the founder and Acting CSO of Beigene Bio. Additional experience includes key roles at GlaxoSmithKline and Merck & Co. Pearl holds a Ph.D. in Molecular Biology from Princeton University and an SB in Life Sciences from the Massachusetts Institute of Technology.